Ocular Therapeutix (OCUL) Receivables - Other (2013 - 2017)

Ocular Therapeutix (OCUL) posted quarterly Receivables - Other of $688000.0 for Q1 2017, up 68700.0% on a QoQ basis from $1000.0 in Q3 2014.

Ocular Therapeutix (OCUL) Receivables - Other (2013 - 2017) Analysis & Trends

Ocular Therapeutix has reported Receivables - Other for 3 years, with the latest figure at $688000.0 in Q1 2017.

Receivables - Other for Q1 2017 came in at $688000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2017 was $688000.0 (changed N/A YoY), and the FY2013 annual result was $19000.0, changed N/A from the prior year.
Receivables - Other advanced to $688000.0 in Q1 2017, from $1000.0 in the prior quarter.
Over five years, Receivables - Other peaked at $688000.0 in Q1 2017 and troughed at $1000.0 in Q2 2014.
A 3-year average of $177250.0 and a median of $10000.0 in 2013 frame the typical range for Receivables - Other.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Ocular Therapeutix	2.20 Bn	2.20 Bn	11.46 Mn

Download Data